Acadia Pharmaceuticals | ACAD - Trade Creditors


Acadia Pharmaceuticals reported $21.75M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 21.75M 1.65M Sep/2025
ALKERMES USD 68M 31.21M Sep/2025
Alnylam Pharmaceuticals USD 115.72M 1.87M Dec/2025
Biogen USD 432M 18.9M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Bristol-Myers Squibb USD 4.29B 1.14B Sep/2025
Cara Therapeutics USD 2.42M 2.42M Jun/2025
Corcept Therapeutics USD 34.45M 10.92M Sep/2025
Cytokinetics USD 22.08M 46.46M Sep/2025
Eisai JPY 85.49B 4.76B Dec/2025
Eli Lilly USD 5.38B 1.12B Dec/2025
Incyte USD 1.63B 1.46B Dec/2025
J&J USD 11.99B 2.37B Dec/2025
Moderna USD 317M 50M Dec/2025
Neurocrine Biosciences USD 545.5M 425.6M Dec/2025
Pfizer USD 5.02B 142M Sep/2025
Prothena USD 10.5M 1.7M Sep/2025
PTC Therapeutics USD 45.49M 8.87M Dec/2025
Sarepta Therapeutics USD 94.02M 42.69M Sep/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024
Vertex Pharmaceuticals USD 3.43B 600.9M Dec/2025